Clinical trials: Suppurative Hidradenitis
Hidradenitis Suppurativa, Acne Inversa
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other…
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
- Trial name
- NCT04019041
- Testing
- bermekimab
- Where
- 33 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens…
- Trial name
- NCT04179175
- Testing
- secukinumab
- Where
- 191 sites in United States, Argentina and 36 more
- Volunteers
- 702 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NOVA (NCT03628924)
- Testing
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 184 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
This study is open to adults with a chronic inflammatory skin disease called hidradenitis suppurativa. The purpose of this study is to find out whether a medicine called spesolimab helps people with moderate to severe…
- Trial name
- NCT04762277
- Testing
- Spesolimab - solution for infusion, Spesolimab- solution for injection
- Where
- 25 sites in United States, Australia and 10 more
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa, Surgical Wound
Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery
Hidradenitis suppurativa (HS) is a chronic, severe, inflammatory skin disease associated with pain, drainage, odor, and disability characterized by recurring abscesses, nodules, and tunneling sinuses in intertriginous locations…
- Trial name
- NCT05194969
- Testing
- Wet-to-Dry Dressings, Petrolatum with Non-Stick Gauze
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of North Carolina, Chapel Hill
Hidradenitis Suppurativa
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity.
- Trial name
- NCT04414514
- Testing
- Ruxolitinib 1.5% Cream
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Hidradenitis Suppurativa (HS)
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions.
- Trial name
- NCT04430855
- Testing
- Upadacitinib
- Where
- 26 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER II (NCT01468233)
- Testing
- adalimumab
- Volunteers
- 326 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with…
- Trial name
- NCT03827798
- Testing
- CFZ533, LYS006, MAS825
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa, Acne Inversa
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT03852472
- Testing
- Avacopan
- Where
- 91 sites in United States
- Volunteers
- 435 people
- Sponsor
- Amgen
Hidradenitis Suppurativa
A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.
Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions.
- Trial name
- NCT02781818
- Testing
- Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Hidradenitis Suppurativa
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa.
- Trial name
- NCT05635838
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 20 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
- Trial name
- NCT00918255
- Testing
- adalimumab
- Where
- 26 sites in United States, Denmark and 2 more
- Volunteers
- 154 people
- Sponsor
- Abbott
Hidradenitis Suppurativa
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS.
- Trial name
- NCT05819398
- Testing
- Spesolimab i.v., Spesolimab s.c.
- Where
- 162 sites in United States, Argentina and 33 more
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LYRA (NCT04988308)
- Testing
- Bermekimab, Adalimumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa, Acne Inversa
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period.
- Trial name
- NCT04476043
- Testing
- INCB054707
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 209 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses.
- Trial name
- NCT04582669
- Testing
- Intralesional Triamcinolone 10 mg/mL, Intralesional Triamcinolone 20 mg/mL, Intralesional Triamcinolone 40 mg/mL
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa
Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa
This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on…
- Trial name
- NCT04600375
- Testing
- Verbal consultation, Written Action Plan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas